- Home
- TARA vs DOUG Comparison
TARA vs DOUG Comparison
Compare TARA & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- DOUG
- Stock Information
- Founded
- TARA N/A
- DOUG 1911
- Country
- TARA United States
- DOUG United States
- Employees
- TARA N/A
- DOUG N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- DOUG Building operators
- Sector
- TARA Health Care
- DOUG Real Estate
- Exchange
- TARA Nasdaq
- DOUG Nasdaq
- Market Cap
- TARA 196.8M
- DOUG 225.3M
- IPO Year
- TARA N/A
- DOUG N/A
- Fundamental
- Price
- TARA $5.20
- DOUG $2.56
- Analyst Decision
- TARA Strong Buy
- DOUG
- Analyst Count
- TARA 6
- DOUG 0
- Target Price
- TARA $19.80
- DOUG N/A
- AVG Volume (30 Days)
- TARA 504.0K
- DOUG 382.3K
- Earning Date
- TARA 11-03-2025
- DOUG 11-03-2025
- Dividend Yield
- TARA N/A
- DOUG N/A
- EPS Growth
- TARA N/A
- DOUG N/A
- EPS
- TARA N/A
- DOUG N/A
- Revenue
- TARA N/A
- DOUG $1,034,406,000.00
- Revenue This Year
- TARA N/A
- DOUG $17.61
- Revenue Next Year
- TARA N/A
- DOUG N/A
- P/E Ratio
- TARA N/A
- DOUG N/A
- Revenue Growth
- TARA N/A
- DOUG 8.69
- 52 Week Low
- TARA $2.21
- DOUG $1.48
- 52 Week High
- TARA $10.48
- DOUG $3.20
- Technical
- Relative Strength Index (RSI)
- TARA 57.60
- DOUG 52.07
- Support Level
- TARA $4.96
- DOUG $2.46
- Resistance Level
- TARA $5.32
- DOUG $2.89
- Average True Range (ATR)
- TARA 0.30
- DOUG 0.13
- MACD
- TARA -0.11
- DOUG 0.01
- Stochastic Oscillator
- TARA 15.55
- DOUG 69.81
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.